Press Release

Cooley Advises on Nightstar + NuCana IPOs

Pair of transactions highlight strength across life sciences sector public offerings
October 10, 2017

Palo Alto – October 10, 2017 – Cooley recently advised on the initial public offerings for UK life sciences companies Nightstar Therapeutics and NuCana. These transactions are the latest example of Cooley’s commitment and leadership in the life sciences sector.

Cooley partners Marc Recht, Brian Leaf, Div Gupta, Stephen Rosen and Ed Lukins led the cross-office team advising Nightstar on its $86 million IPO of 6,164,000 American Depositary Shares, which includes the full exercise of the underwriters’ option to purchase additional shares. Nightstar, which now trades on The NASDAQ Global Select Market under the symbol “NITE,” is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases.

Cooley partners Div Gupta, Brent Siler, Nicole Brookshire and Ed Lukins advised the underwriters on NuCana’s $114 million IPO of 7,596,505 American Depositary Shares, which includes the partial exercise of the underwriters’ option to purchase additional shares. NuCana, which now trades on The NASDAQ Global Select Market under the symbol “NCNA,” is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying its technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. Citigroup, Jefferies and Cowen acted as joint book-running managers for the offering, and William Blair acted as co-manager.

In August, Cooley advised Zealand Pharma on its $89 million IPO, which followed on the heels of a series of four life sciences transactions, including the IPOs for Zymeworks, Verona, UroGen and Biohaven.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.